Impact of Single Center Treatment on Ewing Sarcoma 10-Year Long Term Survival Rates

Area of Science:

• Oncology
• Orthopedic Surgery
• Pediatric Oncology

Background:

• Ewing sarcoma is a significant malignant bone tumor in children and adolescents.
• Systemic chemotherapy protocols have improved outcomes over three decades.
• Local treatment combined with chemotherapy is standard care.

Purpose of the Study:

• To determine survival rates and prognostic factors for Ewing sarcoma patients treated at a single center.
• To compare single-center data with multicenter study results.
• To evaluate the impact of treatment strategies on Ewing sarcoma outcomes.

Main Methods:

• Retrospective analysis of 38 patients treated at a single institution.
• Surgery combined with radiotherapy in 55.3% of cases.
• Median follow-up of 8.2 years.

Main Results:

• Single-center survival rates for metastasis-free and disseminated disease were 90.5% and 50%, respectively.
• Patients responding well to chemotherapy had an 83.3% survival rate.
• Younger patients (<15 years) had higher overall survival (82.4%) than older patients (73.3%).
• Multicenter studies reported lower survival rates (metastasis-free ~60%, metastasis <40%).

Conclusions:

• Single-center treatment at a qualified institution yields superior survival rates for Ewing sarcoma.
• Effective Ewing sarcoma management relies on a multidisciplinary approach.
• Close collaboration between oncological teams and experienced surgeons is vital.